BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Head and neck cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
1646 results:

  • 1. Enhanced CTLA-4 blockade anti-tumor immunity with APG-157 combination in a murine head and neck cancer.
    Shin DS; Basak S; Veena MS; Comin-Anduix B; Bhattacharya A; Dong TS; Ko A; Han P; Jacobs J; Moatamed NA; Avila L; Pellegrini M; Wang M; Srivatsan ES
    Cancer Med; 2024 May; 13(9):e7212. PubMed ID: 38686626
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
    Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
    [No Abstract]    [Full Text] [Related]  

  • 3. Difference between Keratinized- and Non-Keratinized-Originating Epithelium in the Process of Immune Escape of Oral Squamous Cell Carcinoma.
    Kitsukawa Y; Fukumoto C; Hyodo T; Komiyama Y; Shiraishi R; Koike A; Yagisawa S; Kunitomi Y; Hasegawa T; Kotani W; Ishida K; Wakui T; Kawamata H
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612630
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Phase Ⅱ clinical trial of pd-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
    Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
    [No Abstract]    [Full Text] [Related]  

  • 5. Enhanced oral versus flank lymph node T cell response parallels anti-pd1 efficacy in head and neck cancer.
    Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
    Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. pd-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
    Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
    Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.
    Ji G; Yang Q; Wang S; Yan X; Ou Q; Gong L; Zhao J; Zhou Y; Tian F; Lei J; Mu X; Wang J; Wang T; Wang X; Sun J; Zhang J; Jia C; Jiang T; Zhao MG; Lu Q
    Genome Med; 2024 Apr; 16(1):49. PubMed ID: 38566201
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Correlation Between ImageJ and Conventional Manual Scoring Methods for Programmed Death-Ligand 1 Immuno-Histochemically Stained Sections.
    Al Taher RS; Abbas MA; Halahleh K; Sughayer MA
    Technol Cancer Res Treat; 2024; 23():15330338241242635. PubMed ID: 38562094
    [No Abstract]    [Full Text] [Related]  

  • 9. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Dang S; Li X; Liu H; Zhang S; Li W
    Cancer Med; 2024 Apr; 13(7):e7119. PubMed ID: 38553943
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-pd-1 therapy resistance.
    Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
    Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. RNA splicing regulator EIF3D regulates the tumor microenvironment through immunogene-related alternative splicing in head and neck squamous cell carcinoma.
    Lu D; Mihoayi M; Ablikim Y; Arikin A
    Aging (Albany NY); 2024 Mar; 16(7):5929-5948. PubMed ID: 38535990
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. M6A-mediated molecular patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma.
    Wang Y; Peng L; Wang F
    Cancer Biol Ther; 2024 Dec; 25(1):2333590. PubMed ID: 38532632
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-pd-1/PD-L1 therapy in advanced NSCLC.
    Polcaro G; Liguori L; Manzo V; Chianese A; Donadio G; Caputo A; Scognamiglio G; Dell'Annunziata F; Langella M; Corbi G; Ottaiano A; Cascella M; Perri F; De Marco M; Col JD; Nassa G; Giurato G; Zeppa P; Filippelli A; Franci G; Piaz FD; Conti V; Pepe S; Sabbatino F
    Mol Cancer; 2024 Mar; 23(1):63. PubMed ID: 38528526
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Treatments on the horizon for locally advanced basal cell carcinoma.
    Idriss MH; Stull CM; Migden MR
    Cancer Lett; 2024 May; 589():216821. PubMed ID: 38521198
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Lymphatic endothelial cell-mediated accumulation of CD177
    Ma M; Li L; Yang SH; Huang C; Zhuang W; Huang S; Xia X; Tang Y; Li Z; Zhao ZB; Chen Q; Qiao G; Lian ZX
    Oncoimmunology; 2024; 13(1):2327692. PubMed ID: 38516269
    [TBL] [Abstract] [Full Text] [Related]  

  • 16.
    Cytryn SL; Pandit-Taskar N; Lumish MA; Maron SB; Gu P; Ku GY; Chou JF; Capanu M; Antoine A; Loegel D; Feder L; Philemond S; Lyashchenko SK; Lewis JS; Paroder V; Srivastava A; Tang LH; Schoder H; Janjigian YY
    J Nucl Med; 2024 May; 65(5):722-727. PubMed ID: 38514081
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.
    Jiang Y; Zheng Y; Zhang YW; Kong S; Dong J; Wang F; Ziman B; Gery S; Hao JJ; Zhou D; Zhou J; Ho AS; Sinha UK; Chen J; Zhang S; Yin C; Wei DD; Hazawa M; Pan H; Lu Z; Wei WQ; Wang MR; Koeffler HP; Lin DC; Jiang YY
    Nat Commun; 2024 Mar; 15(1):2484. PubMed ID: 38509096
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of head and neck Squamous Cell Carcinoma.
    Zhou R; Wang J
    Crit Rev Immunol; 2024; 44(4):61-78. PubMed ID: 38505922
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.
    Kelly RJ; Landon BV; Zaidi AH; Singh D; Canzoniero JV; Balan A; Hales RK; Voong KR; Battafarano RJ; Jobe BA; Yang SC; Broderick S; Ha J; Marrone KA; Pereira G; Rao N; Borole A; Karaindrou K; Belcaid Z; White JR; Ke S; Amjad AI; Weksler B; Shin EJ; Thompson E; Smith KN; Pardoll DM; Hu C; Feliciano JL; Anagnostou V; Lam VK
    Nat Med; 2024 Apr; 30(4):1023-1034. PubMed ID: 38504015
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 83.